We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline... Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. Show more
Actively Exploring Partnership for Alzheimerโs DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a...
ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc.ย (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
ROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 0.857142857143 | 3.5 | 3.9499 | 3.04 | 55548 | 3.36634184 | CS |
4 | 0.6937 | 24.4579205303 | 2.8363 | 4.81 | 2.74 | 170308 | 3.32327129 | CS |
12 | -1.68 | -32.245681382 | 5.21 | 6 | 1.39 | 98583 | 3.04027431 | CS |
26 | -1.97 | -35.8181818182 | 5.5 | 8.9 | 1.39 | 87947 | 4.50708484 | CS |
52 | -9.1148 | -72.0833860559 | 12.6448 | 13.02 | 1.39 | 75179 | 6.56518049 | CS |
156 | -342.97 | -98.9812409812 | 346.5 | 478.8 | 1.39 | 291358 | 152.7268845 | CS |
260 | -979.27 | -99.6408221408 | 982.8 | 2568.3 | 1.39 | 582220 | 674.8200854 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions